Treos Bio announces results from trial of precision cancer vaccine
Category: #health  By Mateen Dalal  Date: 2019-05-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Treos Bio announces results from trial of precision cancer vaccine

Preliminary outcomes of the first part of the study have been made available and results of the second part are anticipated to be published in the third quarter of this year.

The immuno-oncology company Treos Bio Ltd. has reportedly announced the positive interim outcomes from its first-in-man phase 1/2 trial of its precision cancer vaccine with maintenance therapy in patients enduring metastatic colorectal cancer (mCRC). The results will be presented in a poster session at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3.

Reportedly, PolyPEPI1018 is an off-the-shelf, long peptide vaccine consists of twelve unique epitopes developed from 7 conserved cancer testis antigens (CTAs) regularly stated in mCRC. PolyPEPI1018 was created to bring on polyvalent T cell responses in a large subpopulation of CRC patients leveraging PEPI TestTM platform. This platform identifies Personal EPItopes (PEPIs) which may induce antigen-specific T cell responses in a subject.

Apparently, the Phase 1/2 study is a single-arm, open-label, multicenter study to assess the tolerability, safety, preliminary efficacy and immunogenicity of single (first part of the study) or multiple (second part of the study) subcutaneous injection of PolyPEPI1018 as an additional immunotherapy to the standard-of-care maintenance treatment in patients enduring metastatic colorectal cancer. Preliminary outcomes of the first part of the study have been made available and results of the second part of the study are anticipated to be published in the third quarter of this year.

Immunological data observed so far for PolyPEPI1018 off-the-shelf vaccine against mCRC outperformed has noted immunogenicity of modified neoantigen vaccines and enabled durable treatment effect as supplement to maintenance therapy.

Joleen M. Hubbard M.D., Principal Investigator, OBERTO trial, Mayo Clinic, reportedly stated that despite the single dose of PolyPEPI1018, the company has seen unexpected clinical signals in the first part of the study. Based on these encouraging results, the trial has been amended to administer three doses of PolyPEPI1018 given 12 weeks apart, he further added.

Source link: http://treosbio.com/index.php/may-28-2019/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

AgraFlora announces acquisition of outstanding shares of Sanna
AgraFlora announces acquisition of outstanding shares of Sanna
By Mateen Dalal

  Under the agreement terms, the company is required to pursue the acquisition of 100% of Sanna’s outstanding shares. The acquisition is anticipated to amplify the production capacity of AgraFlora to two times the current production by...

NantKwest announces Phase 1 results of PD-L1.t-haNK cell therapy
NantKwest announces Phase 1 results of PD-L1.t-haNK cell therapy
By Mateen Dalal

NantKwest Inc., a U.S.-based clinical-stage immunotherapy company, has reportedly announced encouraging safety data generated from the first six patients in its QUILT-3.064 clinical trial. The study is conducted to access the preliminary efficac...

Twitter launches a central hub for privacy and data protection info
Twitter launches a central hub for privacy and data protection info
By Mateen Dalal

  New website will host information on Twitter’s new privacy products and announcements Twitter is also looking to change its current data protection and privacy terms Twitter has recently launched a new website called Twitter Privac...